Pharmacological effects Side effects Contraindications Uses Usage and Dosage Precautions Drug Interactions
ChemicalBook > CAS DataBase List > Etoposide

Etoposide

Pharmacological effects Side effects Contraindications Uses Usage and Dosage Precautions Drug Interactions
Product Name
Etoposide
CAS No.
33419-42-0
Chemical Name
Etoposide
Synonyms
epe;vepesid;VP-16;Toposar;Celltop;epec;nk171;e[qr];Etopl;lastet
CBNumber
CB8270005
Molecular Formula
C29H32O13
Formula Weight
588.56
MOL File
33419-42-0.mol
More
Less

Etoposide Property

Melting point:
236-251 °C (lit.)
alpha 
D20 -110.5° (c = 0.6 in chloroform)
Boiling point:
563.9°C (rough estimate)
Density 
1.2966 (rough estimate)
refractive index 
-110.5 ° (C=0.6, CHCl3)
storage temp. 
2-8°C
solubility 
DMSO: 30 mg/mL
form 
powder
pka
9.8(at 25℃)
color 
white
Water Solubility 
Insoluble in water.
Merck 
14,3886
BCS Class
4
Stability:
Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months
IARC
1 (Vol. 76, 100A) 2012, 1 (Vol. 76, 100A) 2012
EPA Substance Registry System
Etoposide (33419-42-0)
More
Less

Safety

Hazard Codes 
T,Xi
Risk Statements 
45-22-36/37/38
Safety Statements 
53-45-36/37-26
RIDADR 
3249
WGK Germany 
3
RTECS 
KC0190000
HazardClass 
6.1(a)
PackingGroup 
II
HS Code 
29389090
Hazardous Substances Data
33419-42-0(Hazardous Substances Data)
Toxicity
LD50 oral in rabbit: 147mg/kg
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Danger
Hazard statements

H302Harmful if swallowed

H350May cause cancer

H412Harmful to aquatic life with long lasting effects

Precautionary statements

P201Obtain special instructions before use.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P308+P313IF exposed or concerned: Get medical advice/attention.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
SRP2017
Product name
GAL4 [(1-147) + VP16 (411-490)] from Saccharomyces cerevisiae human herpesvirus 2
Purity
recombinant, expressed in E. coli, ≥80% (SDS-PAGE)
Packaging
10μg
Price
$425
Updated
2024/03/01
Sigma-Aldrich
Product number
SRP2017
Product name
GAL4 [(1-147) + VP16 (411-490)] from Saccharomyces cerevisiae human herpesvirus 2
Purity
recombinant, expressed in E. coli, ≥80% (SDS-PAGE)
Packaging
500μG
Price
$16790
Updated
2024/03/01
Sigma-Aldrich
Product number
E1383
Product name
Etoposide
Purity
synthetic, 98.0-105.0%, powder
Packaging
25mg
Price
$82.4
Updated
2024/03/01
Sigma-Aldrich
Product number
BP885
Product name
Etoposide
Purity
British Pharmacopoeia (BP) Reference Standard
Packaging
150MG
Price
$257
Updated
2024/03/01
Sigma-Aldrich
Product number
341205
Product name
Etoposide - CAS 33419-42-0 - Calbiochem
Packaging
25mg
Price
$71.1
Updated
2024/03/01
More
Less

Etoposide Chemical Properties,Usage,Production

Pharmacological effects

The chemical name of etoposide is 9-(4, 6-O-ethylidene-β-D-glucopyranoside)-4'-demethyl-epipodophyllotoxin. It is an off-white crystalline powder and is odorless. Upon being exposed to light, heat, its color is easy to change. It is also hydroscopic. It is almost insoluble in water, slight soluble in methanol, dimethyl sulfoxide and also ethanol.
Etoposide is the newly semi-synthetic derivative of epipodophyllotoxin and belongs to mitotic inhibitors which can make the cells be stalled in the mid-mitosis stage. It is a cell cycle specific anticancer drug. This product can act on the DNA topoisomerase II (Topo II), to form a "Drug-enzyme-DNA" complex, preventing Topo II from participating in DNA repair, resulting in the stallation of DNA replication, thereby inhibiting the proliferation of tumor cell(IC 50 = 59.2 μ M). It mainly takes effects on S phase, G2 phase cells, and caused cell arrest in the G2 phase. The experimental study has found that the complex can be reversed with the elimination of drug. In that case, Top II will become free again so the damaged DNA get repair again, reducing its anti-tumor effect. Therefore, extending the treatment time can enhance the anti-tumor activity. It is mainly used for the treatment of small cell lung cancer, malignant lymphoma, malignant germ cell tumors, and leukemia and also has certain efficacy on treating neuroblastoma, rhabdomyosarcoma, ovarian cancer, non-small cell lung cancer, stomach cancer and esophageal cancer.
This product has a bioavailability of 48% (25% to 74%) after oral administration. The plasma concentration can reach peak at 0.5 to 4 hours after taking this drug. After intravenous injection of this product, the plasma concentration of this drug exhibits biphasic elimination with the half-life of α phase being (1.4 ± 0.4) h and half-life of β phase being (5.7 ± 1.8) hours. The plasma protein binding rate is 74% to 90% with the highest concentration being found in intestine, liver, and kidney while the drug concentration in the cerebrospinal liquid is only 2% to 10% of that in the blood. It is primarily subject to renal excretion with 45% being excreted in the urine at 72 hours after the administration wherein prototype accounts for two-thirds and metabolites account for 15%. 1.5% to 16% of the drug is excreted through from faeces via the bile.

Side effects

1. Over-rapid intravenous infusion rate (less than 30 minutes for the first time of administration) may cause rash, chills, fever, bronchospasm, dyspnea and other allergic reactions.
2. The drug can cause obvious myelosuppression reaction including anemia, leukopenia and thrombocytopenia. This frequently occurs in 7 to 14 days after treatment and can recover after 20 days of stopping administration. Severe neutropenia is the dose-limiting toxicity of the drug.
3. There may be loss of appetite, nausea, vomiting, stomatitis, diarrhea, abdominal pain and constipation. Liver toxicity is rare and may be accompanied with increased level of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, lactate dehydrogenase and bilirubin.
4. There may be occasional elevated level of blood urea nitrogen.
5. There may be dizziness, fatigue and tiredness with occasional numbness, headaches and so on; there may be heart palpitations, ECG changes, hypotension; interstitial pneumonia may also occur; hair loss is also common.

Figure 1 the structural formula of etoposide

Contraindications

1. Patients of significantly lower amount of white blood cells and platelets should be disabled.
2. Patients of heart, liver and kidney dysfunction should be disabled.
3. Pregnant women and lactating women should be disabled.
4. Patients allergic to this drug should be disabled.

Uses

It is used as anti-cancer drug mainly used for the treatment of small cell lung cancer, testicular cancer, malignant lymphoma and acute leukemia. It also has certain efficacy in treating neuroblastoma, rhabdomyosarcoma, ovarian cancer, non-small cell lung cancer, stomach cancer and breast cancer.

Usage and Dosage

1. Oral: single-administration; daily: 60~100mg /m2; continuously apply for 10 days and repeat every 3 to 4 weeks. For combination chemotherapy, apply 50 mg/m2 per day and continue to take 3 or 5 days.
2. Intravenous infusion: Use sodium chloride injection for dilute this product of required amount (this drug is instable in 5% glucose injection and can form a fine precipitate). The concentration should not be more than 0.25 mg/ml with the intravenous infusion time being not less than 30 minutes.
Solid tumors: 60~100mg/m2 per day; continue for 3 to 5 days with repeating the medication every 3 to 4 weeks.
Leukemia: 60~100mg/m2 per day; apply for 5 consecutive days; repeat the medication at certain interval according to the blood condition.
Common pediatric dose: for intravenous infusion, administer based on volume/surface area 100~150mg/m2 for continuous 3 to 4 days.

Precautions

1. This product is not suitable for intravenous injection and the intravenous infusion rate should not be too fast and should at least last for half an hour, otherwise it can easily lead to hypotension, laryngeal spasm and other allergic reactions.
2. Don’t choose chest, abdomen and intrathecal injection for administration.
3. During the medication period, the patients should be subject be regular investigation on the peripheral blood condition as well as liver and kidney function.
4. This product should be administrated immediately after dilution. If precipitate occurs, it should be strictly prohibited.
5. This product can cause reproductive toxicity and teratogenicity to animals and can be excreted through breast milk. FDA provided the pregnancy safety of this drug being classified as D class.
This information is edited by Xiongfeng Dai from Chemicalbook.

Drug Interactions

1. Because this product has significant bone marrow suppression effect and should be taken care of when be used in combination with other anticancer drugs.
2. This product can inhibit the body's immune defense mechanism, so that vaccination is not able to stimulate the body to produce antibodies.
3. Within 3 months after the end of chemotherapy, it is not recommended for applying the vaccine virus.
4. This product has a high binding rate to the plasma protein and therefore, the drug bound to plasma protein can affect the excretion of this product.

Description

Etoposide is a plant alkaloid and an inhibitor of topoisomerase II (IC50 = 60.3 μM). It inhibits proliferation of a variety of adenocarcinoma cells (IC50s = 0.005-12,200 μM) and human umbilical vein endothelial (HUVEC) cells (IC50 = 0.249 μM). It reduces tumor growth in an Ma human embryonal carcinoma mouse xenograft model when administered at a dose of 25 mg/kg, an effect that is enhanced by concomitant administration of the immunosuppressant cyclosporin A . Etoposide also inhibits nuclear receptor coactivator 3 (IC50 = 2.48 μM). Formulations containing etoposide have been used in combination therapy in the treatment of cancer.

Chemical Properties

White or almost white, crystalline powder, slightly hygroscopic

Originator

Etopos,Lemery,Mexico

Uses

An antitumur agent that complexes with topoisomerase II and DNA to enhance double-strand and single strand cleavage of DNA and reversible inhitit religation. Blocks the cell cycle in S-phase and G2-phase of the cell cycle. Induces apoptosis in nor

Uses

anticonvulsant

Uses

Etoposide is used for germinogenic tumors, ovarian, stomach, and lung cancer, Hodgkin’s disease, and non-Hodgkin’s lymphoma for both monotherapy and in combination therapy.

Uses

A DNA topoisomerase II inhibitor. Semi-synthetic derivative of podophyllotoxin, related structurally to Teniposide. Antineoplastic.

Definition

ChEBI: Etoposide is a beta-D-glucoside, a furonaphthodioxole and an organic heterotetracyclic compound. It has a role as an antineoplastic agent and a DNA synthesis inhibitor. It is functionally related to a podophyllotoxin and a 4'-demethylepipodophyllotoxin.

Indications

Etoposide (VePesid) is a semisynthetic derivative of podophyllotoxin that is produced in the roots of the American mandrake, or May apple. Unlike podophyllotoxin and vinca alkaloids, etoposide does not bind to microtubules. It forms a complex with the enzyme topoisomerase II, which results in a single-strand breakage of DNA. It is most lethal to cells in the S- and G2-phases of the cell cycle. Drug resistance to etoposide is thought to be caused by decreased cellular drug accumulation.
Etoposide is most useful against testicular and ovarian germ cell cancers, lymphomas, small cell lung cancers, and acute myelogenous and lymphoblastic leukemia.Toxicities include mild nausea, alopecia, allergic reaction, phlebitis at the injection site, and bone marrow toxicity.

Manufacturing Process

Preparation of 2,3-Di-O-dichloroacetyl-(4,6-O-ethylidene)-β-D-glucopyranose (hydrogenolysis)
An over-dried 100 mL three-necked round bottom flask fitted with a stir bar, low temperature thermometer, and H2 inlet was charged with 2,3-di-Oetoposide dichloroacetyl-1-O-benzyloxycarbonyl-(4,6-O-ethylidene)-β-D-glucopyranose (1.8 mmol), in acetone (15-30% concentration) and 10% palladium on activated carbon powder (0.2 mmol). The solution was stirred until uniform and then cooled to -10°C to 0°C. After the reaction was over the catalyst was filtered over sintered glass containing a plug of celite under reduced pressure. The sintered glass is washed trice with one times the total reaction volume of anhydrous acetone and the filtrates are pooled and then concentrated to dryness under reduced pressure at a temperature close to 30°C. The crude residue was dried under vacuum at ambient temperature and above compound was thus obtained as white foam in 98% yield with a melting point of 130°-132°C (from acetone).
Preparation of 4'-Demethyl-epi-podophyllotoxin-4-(2,3-di-O-dichloroacetyl- 4,6-O-ethylidene)-β-D-glucopyranoside
An oven-dried, three-neck 250 mL round bottom flask was fitted with a stir bar, low temperature thermometer, septa and argon inlet, was introduced with 4'-demethyl-epi-podophyllotoxin (1 mmol), dry molecular sieve (1/16 δ pellets) and anhydrous dichloromethane (20-50% concentration). 2-3-Di-Odichloroacetyl-( 4,6-O-ethylidene)-β-D-glucopyranose (1.7 mmol) in dichloromethane (10-20% concentration) was added via double-ended needle. The suspension was stirred until homogenous and then cooled to -40°C to - 60°C in an atmosphere of argon and in the absence of moisture. To the stirred suspension was added via a syringe, trimethylsilyl trifluoromethane sulfonate (2 mmol) over 30 minutes. The reaction was held at between -50°C and - 40°C for 30 minutes. The course of the coupling reaction was monitored by thin layer chromatography. The suspension was allowed to warm to about - 30°C and filtered through a short celite/basic alumina column, eluting twice with one times the total reaction volume of dichloromethane. The pooled filtrate was evaporated under reduced pressure to yield the crude intermediate product 4'-demethyl-epi-podophyllotoxin-4-(2,3-di-Odichloroacetyl- 4,6-O-ethylidene)-β-D-glucopyranose (yield 80%). This crude product is used directly in the next step without any purification. A sample was purified by the chromatraton for spectroscopic identification. The results are as follows: m.p.: 242°-243°C (from methanol).
Preparation of 4-Demethyl-epi-podophyllotoxin-4-(4,6-O-ethylidene)-β-Dglucopyranose (etoposide)
To 0.8 mmol of 4'-demethyl-epi-podophyllotoxin-4-(2,3-di-O-dichloroacetyl- 4,6-O-ethylidene)-β-D-glucopyranose in 10-25% concentration in methanol is added 1.5 mmol of zinc acetate dihydrate. The reaction mixture is refluxed with stirring under heating for 90 minutes. After completion of the reaction, the mixture is cooled and the volume reduced to one third by rotary evaporation under reduced pressure. Working up is effected by diluting the reaction solution with 100 mL dichloromethane and 100 mL of water. The aqueous phase was washed with 50 mL of dichloromethane. The combined dichloromethane phases was washed twice with 50 mL water, 15 mL of methanol was added to the first wash to prevent precipitation of etoposide. The organic phase was dried over anhydrous sodium sulphate, filtered and concentrated by evaporation under vacuum to an amorphous solid. This solid was re-crystallized from methanol/n-pentane at -4°C to 0°C, thus obtaining colorless amorphous powder of Etoposide (yield 68%), if the mother liquors are treated the yield will be higher). Melting point: 256°-258°C.
Preparation of Etoposide employing 2,3-di-O-dichloroacetyl-(4,6-Oethylidene)- β-D-glucopyranose and boron trifluoride etherate as catalyst
4'-Demethyl-epi-podophyllotoxin (1 mmol) and 2,3-di-O-dichloroacetyl-(4,6- O-ethylidene)-β-D-glucopyranose (2 mmol) were introduced into dry dichloromethane under anhydrous condition. When the temperature was stabilized to -20°C to -30°C, boron trifluoride etherate (1.5 mmol) was added slowly with stirring. Reaction was continued at this temperature and monitored by thin layer chromatography. After the completion of the reaction as evidenced by TLC, the solution was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford the crude intermediate product 4'-demethyl-epi-podophyllotoxin-4-(2,3-di-Odichloroacetyl- 4,6-O-ethylidene)-β-D-glucopyranose. This crude product was then converted to etoposide by following the procedure as above described. The yield of final product etoposide was about 60%.

brand name

Toposar(Sicor); Vepesid (Bristol-Myers Squibb).

Therapeutic Function

Antitumor, Antineoplastic

General Description

Etoposide is available in 50- and 100-mg capsules for oral useand in 100-mg vials for IV use. The agent is approved for usein testicular cancer and small cell lung cancer. It has alsobeen used in a wide variety of cancers including NSCLC,Hodgkin’s and non-Hodgkin’s disease, Kaposi sarcoma,acute lymphocytic leukemia, neuroblastoma, choriocarcinoma,and epithelial, ovarian, testicular, gastric, endometrial,and breast cancers. Etoposide is one of the few natural productderivatives that can be administered orally. When givenby this route, bioavailability is 50%. Administration by the IVroute is also utilized, and the drug is widely distributed whengiven by either route. The agent is highly protein bound(90%) primarily to albumin. Low albumin levels may lead toan increase in free drug and require a lowering of the dose.The drug does not penetrate the blood-brain barrier at normaldoses but does during high-dose therapy. Elimination occursprimarily in the urine with 30% to 40% of an IV dose appearingas unchanged drug. The elimination half-life is 5 to 10hours. Metabolism involves opening of the lactone ring togive the hydroxy acid as the major metabolite. Epimerizationoccurs at C-3 to give the cis-lactone, which may also undergohydrolysis to give the hydroxy acid. Glucuronidation and sulfationof the 4'-OH give products that are inactive. Activemetabolites are formed as a result of CYP3A4 mediated oxidative-O-demethylation of the 3'-methoxy group to give thecatechol followed by oxidation to give the quinone. The toxicitiesof etoposide include dose-limiting myelosuppression,produces nausea and vomiting in 30% to 40% of patients,which is more commonly seen when the drug is administeredorally. The agent also produces anorexia, alopecia, mucositis,and hypersensitivity reactions that may be caused by etoposideor Cremophor EL (polyoxyethylated castor oil), which isused as a vehicle for IV administration of the drug. Leukemia,especially acute myelogenous leukemia, has been associatedwith the drugs’ ability to produce strand breaks with resultanttranslocation of genetic material. The leukemias are generallyseen 5 to 8 years posttreatment and have been associated withtranslocation of several different genes resulting in breakpointsaround the mixed lineage leukemia (MLL) gene.Transcription and translation of this altered DNA giveschimeric proteins, which form partly from the translocatedgene and partly from the MLL gene. Exactly how thesechimeric proteins lead to leukemia is not known, but similaralterations are seen with other topoisomerase inhibitors.

Biochem/physiol Actions

Etoposide is an antitumor agent that complexes with topoisomerase II and DNA to enhance double-strand and single-strand cleavage of DNA and reversibly inhibit religation. Blocks the cell cycle in in S-phase and G2-phase of the cell cycle; induces apoptosis in normal and tumor cell lines; inhibits synthesis of the oncoprotein Mdm2 and induces apoptosis in tumor lines that overexpress Mdm2.

Clinical Use

Etoposide is utilized in the treatment of small cell lung cancer and in combination with other agents in refractory testicular cancer.

Safety Profile

Poison by ingestion, intraperitoneal, intravenous, and subcutaneous routes. An experimental teratogen. Human systemic effects by ingestion and inhalation: agranulocytosis, aplastic anemia, and other changes in bone marrow. Experimental reproductive effects. Human mutation data reported. When heated to decomposition it emits acrid smoke and fumes.

Synthesis

Etoposide, [[5R-(5|á,5a|?,8a|á,9|?)]-9-[4,6-O-ethylidene-|?-D-glucopyranosyl) oxy]-] 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3,4: 6,7]-naphtho[2,3- d]-1,3-dioxol-6(5aH)-one (30.4.5), is made from 4-desmethylepipodophyllotoxin (30.4.3), the phenolic group of which being previously protected by benzyl chloroformate, which makes 4-carbobenzyloxy-4-desmethylepipodophyllotoxin (30.4.3). Next, the hydroxyl group at position C9 is esterified with 4,6-O-ethylyden-2,3-di-O-acetyl-|?-D-glucopyranose in the presence of boron trifluoride to make the corresponding glucopyranoside 30.4.4. Removing the acetyl group in the glucopyranosyl part of the molecule using zinc acetate in sodium methoxide, and also removing the benzyloxycarbonyl protection by hydrogenation using a palladium on carbon catalyst gives the desired etoposide (30.4.5).

Drug interactions

Potentially hazardous interactions with other drugs
Anticoagulants: possibly enhanced anticoagulant effect with coumarins.
Antipsychotics: avoid concomitant use with clozapine, increased risk of agranulocytosis.
Ciclosporin: 50% reduction in etoposide clearance.

Metabolism

The drug is more than 96% protein bound, undergoes biphasic elimination, and has a terminal half-life of 4 to 11 hours. Approximately 35 to 45% of a dose is eliminated via the kidneys, with less than 6% excreted in feces. The drug should be used with caution in patients with renal or liver disease.

storage

Store at RT

References

Hande, K. R. "Etoposide: four decades of development of a topoisomerase II inhibitor." European Journal of Cancer34.10(1998):1514.
Noda, K, et al. "Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer." New England Journal of Medicine 346.2(2002):85-91.

Etoposide Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Etoposide Suppliers

Americas 1 Austria 1 Belgium 1 Brazil 2 Canada 6 China 407 Czech Republic 1 Europe 4 France 2 Germany 5 India 43 Israel 2 Japan 6 Jordan 1 Nepal 1 Poland 1 Slovenia 1 South Korea 1 Spain 1 Switzerland 5 United Kingdom 24 United States 67 Venezuela 1 Global 584
Guangzhou Tomums Life Science Co., Ltd.
Tel
020-31155029 18902330969
Fax
020-31155029
Email
sales@tomums.cn
Country
China
ProdList
4698
Advantage
58
Shanghaizehan biopharma technology co., Ltd.
Tel
021-61350663 13052117465
Fax
021-61350662
Email
sales@zehanbiopharma.com
Country
China
ProdList
991
Advantage
55
WUHAN XINXINJIALI BIOTECHNOLOGY Co. LTD.
Tel
027-59223049 15807102573
Fax
027-84666270
Email
lj_xxjlbio@163.com
Country
China
ProdList
278
Advantage
58
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
96815
Advantage
76
Meryer (Shanghai) Chemical Technology Co., Ltd.
Tel
4006608290; 18621169109
Fax
86-21-61259102
Email
market03@meryer.com
Country
China
ProdList
40241
Advantage
62
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Fax
86-21-50328109
Email
3bsc@sina.com
Country
China
ProdList
15848
Advantage
69
Chembest Research Laboratories Limited
Tel
021-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6011
Advantage
61
TCI (Shanghai) Development Co., Ltd.
Tel
021-67121386
Fax
021-67121385
Email
Sales-CN@TCIchemicals.com
Country
China
ProdList
24539
Advantage
81
BeiJing Hwrk Chemicals Limted
Tel
0757-86329057 18501085097
Fax
010-89508210
Email
sales3.gd@hwrkchemical.com
Country
China
ProdList
7583
Advantage
55
Energy Chemical
Tel
021-021-58432009 400-005-6266
Fax
021-58436166
Email
sales8178@energy-chemical.com
Country
China
ProdList
44751
Advantage
61
Wuhan Chemwish Technology Co., Ltd
Tel
86-027-67849912
Fax
86-027-87531808
Email
sales@chemwish.com
Country
China
ProdList
35906
Advantage
56
Beijing Ouhe Technology Co., Ltd
Tel
010-82967028 13552068683
Fax
+86-10-82967029
Email
2355560935@qq.com
Country
China
ProdList
12426
Advantage
60
Adamas Reagent, Ltd.
Tel
400-6009262 16621234537
Fax
021-64823266
Email
zhangsn@titansci.com
Country
China
ProdList
14113
Advantage
59
Chemsky（shanghai）International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com
Country
China
ProdList
32344
Advantage
50
China DongFan Chemical Co.,LTD
Tel
86-0571-85151182
Fax
86-0571-85151182
Country
China
ProdList
5700
Advantage
66
XiaoGan ShenYuan ChemPharm co,ltd
Tel
0712-0712-2580635 15527768850
Email
1791901229@qq.com
Country
China
ProdList
8849
Advantage
52
Shanghai Ennopharm Co., Ltd.
Tel
+86 (21) 6435-5022
Country
China
ProdList
4271
Advantage
65
BEST-REAGENT
Tel
400-1166-196 18981987031
Fax
028-84555506 800101999
Email
cdhxsj@163.com
Country
China
ProdList
11726
Advantage
57
China Langchem Inc.
Tel
0086-21-58956006
Fax
0086-21-58956100
Country
China
ProdList
7815
Advantage
57
Sinopharm Chemical Reagent Co,Ltd.
Tel
86-21-63210123
Fax
86-21-63290778 86-21-63218885
Email
sj_scrc@sinopharm.com
Country
China
ProdList
9823
Advantage
79
Hunan Hui Bai Shi Biotechnology Co., Ltd.
Tel
0731-85526065 13308475853
Email
ivy@hnhbsj.com
Country
China
ProdList
4550
Advantage
62
Spectrum Chemical Manufacturing Corp.
Tel
021-021-021-67601398-809-809-809 15221380277
Fax
021-57711696
Email
marketing_china@spectrumchemical.com
Country
China
ProdList
9664
Advantage
60
Wuhan Fortuna Chemical Co., Ltd
Tel
027-027-59207852 13308628970
Fax
QQ3130921841
Email
buy@fortunachem.com
Country
China
ProdList
2893
Advantage
58
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
Country
China
ProdList
4647
Advantage
58
BioBioPha Co., Ltd.
Tel
0871-65217109 13211707573;
Fax
0871-65215563
Email
y.liu@mail.biobiopha.com
Country
China
ProdList
5654
Advantage
65
ShangHai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847 13636370518
Fax
021-55068248
Email
shyysw007@163.com
Country
China
ProdList
4941
Advantage
60
T&W GROUP
Tel
021-61551611 13296011611
Fax
＋86 21-50676805
Email
contact@trustwe.com
Country
China
ProdList
9900
Advantage
58
Shanghai civi chemical technology co.,Ltd
Tel
86-21-34053660
Fax
86-21-34053661
Email
sale@labgogo.com
Country
China
ProdList
9872
Advantage
52
Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Fax
010-65763397
Email
waley188@sohu.com
Country
China
ProdList
12338
Advantage
58
NCE Biomedical Co.,Ltd.
Tel
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Fax
+86-27-87599188
Country
China
ProdList
1494
Advantage
55
Shanghai T&W Pharmaceutical Co., Ltd.
Tel
+86 21 61551611
Fax
+86 21 50676805
Country
China
ProdList
9901
Advantage
58
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Fax
(86) 21-58955996
Email
info@chemexpress.com
Country
China
ProdList
7553
Advantage
61
9ding chemical ( Shanghai) Limited
Tel
4009209199
Fax
86-021-52271987
Email
sales@9dingchem.com
Country
China
ProdList
22519
Advantage
55
UHN Shanghai Research & Development Co., Ltd.
Tel
021-58958002 18930822973
Fax
+86 (21) 5895-8628
Email
SALES@UHNSHANGHAI.COM
Country
China
ProdList
977
Advantage
58
Shanghai Aladdin Bio-Chem Technology Co.,LTD
Tel
400-6206333 18521732826;
Fax
021-50323701
Email
market@aladdin-e.com
Country
China
ProdList
25015
Advantage
65
The future of Shanghai Industrial Co., Ltd.
Tel
021-61552785
Fax
021-55660885
Email
sales@shshiji.com
Country
China
ProdList
9552
Advantage
55
Shanghai Raise Chemical Technology Co.,Ltd
Tel
+86-021-50935922
Fax
+86-021-33847795
Country
China
ProdList
7876
Advantage
55
Shanghai Tauto Biotech Co., Ltd.
Tel
021-51320588
Fax
0086-21-51320502
Email
tauto@tautobiotech.com
Country
China
ProdList
3989
Advantage
66
Guangzhou Isun Pharmaceutical Co., Ltd
Tel
020-39119399 18927568969
Fax
020-39119999
Email
isunpharm@qq.com
Country
China
ProdList
4428
Advantage
55
Nanjing Sunlida Biological Technology Co., Ltd.
Tel
025-57798810
Fax
025-57019371
Email
sales@sunlidabio.com
Country
China
ProdList
3750
Advantage
55
TargetMol Chemicals Inc.
Tel
021-33632979 15002134094
Fax
021-33632979
Email
marketing@targetmol.com
Country
China
ProdList
7934
Advantage
58
Cheng Du Pufeide Biotechnology Co., Ltd.
Tel
028-82610909 13388174823
Fax
8171-1798
Email
scglp@glp-china.com
Country
China
ProdList
1064
Advantage
58
Shanghai Huikai Chemical Technology Co., Ltd.
Tel
021-61995394 18916691159
Email
chemicalsea@163.com
Country
China
ProdList
1975
Advantage
58
Chengdu Herbpurify Co.Ltd.
Tel
18302802153 18981717076
Fax
086-28-85377358
Email
2355253619@qq.com
Country
China
ProdList
1104
Advantage
58
ShangHai Caerulum Pharma Discovery Co., Ltd.
Tel
18149758185
Email
sales-cpd@caerulumpharma.com
Country
China
ProdList
3421
Advantage
58
Wuhan DKY Technology Co.,Ltd.
Tel
27-81302488 18007166089
Fax
027-81302088
Email
info@dkybpc.com
Country
China
ProdList
2024
Advantage
58
Hubei XinyuanShun Chemical Co., Ltd.
Tel
13971561712, 13995564702, 027-50664929
Fax
027-50664927
Email
hbeixys2001@163.com
Country
China
ProdList
3123
Advantage
55
Shanghai JONLN Reagent Co., Ltd.
Tel
400-0066400 13621662912
Fax
021-55660885
Email
422131432@qq.com
Country
China
ProdList
9986
Advantage
55
Shanghai Worldyang Chemical Co.,Ltd.
Tel
021-021-56795766
Fax
+86-21-56795266
Email
sales@worldyachem.com
Country
China
ProdList
9352
Advantage
58
ChemStrong Scientific Co.,Ltd
Tel
0755-0755-66853366 13670046396
Fax
0755-28363542
Email
sales@chem-strong.com
Country
China
ProdList
17982
Advantage
56
More
Less

View Lastest Price from Etoposide manufacturers

Hebei Dangtong Import and export Co LTD
Product
Etoposide 33419-42-0
Price
US $32.00-25.00/grams
Min. Order
100grams
Purity
99%
Supply Ability
100tons
Release date
2023-02-22
Henan Fengda Chemical Co., Ltd
Product
Etoposide 33419-42-0
Price
US $8.00-6.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
g-kg-tons, free sample is available
Release date
2024-04-23
Shaanxi TNJONE Pharmaceutical Co., Ltd
Product
Etoposide 33419-42-0
Price
US $0.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
20tons
Release date
2024-04-15

33419-42-0, EtoposideRelated Search:

Podophyllotoxin 4'-Demethylepipodophyllotoxin 2-S-thiuronium ethanesulfonate Mesna Methotrexate disodium salt Cisplatin Oxaliplatin Vinorelbine tartrate Nedaplatin Carboplatin Estramustine Mitoxantrone hydrochloride EPROSARTAN Eletriptan Impurity D Eletriptan Etoricoxib Etomidate Etofenamate

  • (-)-Etoposide, (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside
  • EtoposideETOPOSIDE</NOBR><br>CAS:33419-42-0<BR>MES-012
  • BMY-40481, Etoposide 4'-Dihydrogenphosphate, VP-16-213
  • Etoposide , 98.0%(LC)
  • Etoposide for system suitability
  • GAL4 [(1-147) + VP16 (411-490)] from Saccharomyces cerevisiae human herpesvirus 2
  • Etoposide, >=98%
  • (5R,5aR,8aR,9S)-9-[[4,6-O-(1R)-Ethylidene-β-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one
  • (5R,5AR,8aR,9S)-9-(((2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dio
  • VP-16
  • VP-16-213
  • epipodophyllotoxin,4’-demethyl-,4,6-o-ethylidene-beta-d-glucopyranoside
  • epipodophyllotoxin,4’-demethyl-,9-(4,6-o-ethylidene-beta-d-glucopyranoside)
  • lastet
  • nk171
  • nsc141540
  • nsc-141540
  • vepesid
  • 4'-DEMETHYLEPIPODOPHYLLOTOXIN 9-(4,6-O-ETHYLIDENE-BETA-D-GLUCOPYRANOSIDE)
  • 4-demethylepipodophyllotoxin-beta-d-ethylideneglucoside
  • Etoposide4-O--D-Galactopyranoside
  • Furo3,4:6,7naphtho2,3-d-1,3-dioxol-6(5aH)-one, 9-4,6-O-(1R)-ethylidene-.beta.-D-glucopyranosyloxy-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)-
  • 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene-β-d-glucopyranoside)
  • Etoposide(α-tipe)
  • 4'-Demethyl-1-O-[4,6-O-(ethylidene)-β-D-glucopyranosyl]epipodophyllotoxin
  • 4'-Demethylepipodophyllotoxin ethylidene-β-D-glucoside
  • Epipodophyllotoxin VP 16213
  • Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-β-D-glucopyranoside (8CI)
  • Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[(4,6-O-ethylidene-β-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, [5R-[5α,5aβ,8aα,9β(R*)]]-
  • Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[[4,6-O-(1R)-ethylidene-β-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)-
  • Toposar
  • trans-Etoposide
  • VP 16 (pharmaceutical)
  • VP 16-123
  • Zuyeyidal
  • Etoposide USP26
  • Etoposide (FDA) USP24 BP98
  • Etoposide BP2000
  • ETOPOSIDE, MM(CRM STANDARD)
  • ETOPOSIDE, EP STANDARD
  • ETOPOSIDE, USP STANDARD
  • ETOPOSIDE, RESOLUTION MIXTURE USP STANDARD
  • ETOPOSIDE, USP 99+%
  • Etoposide,Usp28
  • DEMETHYLEPIPODOPHYLLOTOXIN-BETA-D-ETHYLIDENEGLUCOSIDE
  • ETOPOSIDE (VEPESID)
  • Etoposide (contains ca. 5% Ethanol)
  • Etoposide (VP-16)
  • (8aR,9R)-5-[(7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-isobenzofuro[6,5-f][1,3]benzodioxol-8-one
  • NIZATIDINE EP IMPURITY E HCL (NIZATIDINE AMIDE HCL)
  • Etoposide - CAS 33419-42-0 - Calbiochem
  • [5R-[5α,5aβ,8aα,9β(R*)]]-9-[(4,6-Ο-Ethylidene-β-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6-(5aH)-one
  • (5R,5aα,9S)-9-[[4-O,6-O-[(R)-Ethylidene]-β-D-glucopyranosyl]oxy]-5,8,8aβ,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one
  • Etoposide - In combination with Cisplatin and Bleomycin
  • 9-((4,6-O-Ethylidene-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one
  • [5R-[5alpha,5abeta,8aalpha,9beta(R*)]]-9-[(4,6-O-Ethylidene-beta-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one
  • 9-((4,6-O-Ethylidine-Beta-D-Glucopyranosyl)Oxy)-
  • [5R-[5α,5aβ,8aα,9β(R*)]]-9-[(4,6-0-Ethylidene-α-D-glucopyransoyl)oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naptho[2,3-d]-1,3-dioxol-6-(5aH)-one